Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Lennox Gastaut Syndrome

ClinicalTrials.gov lists 68 trials for Lennox Gastaut Syndrome or a narrower condition beneath it.

MeSH D065768 Nervous System Diseases C10 C16 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 6 Phase 1/2 Phase 1/2 3 Phase 2 Phase 2 6 Phase 3 Phase 3 25 Phase 4 Phase 4 6 Not applicable Not applicable 8 Observational Observational 11 Expanded access Expanded access 3 Phase 1 Phase 1 6 Phase 1/2 Phase 1/2 3 Phase 2 Phase 2 6 Phase 3 Phase 3 25 Phase 4 Phase 4 6 Not applicable Not applicable 8 Observational Observational 11 Expanded access Expanded access 3

Trials per phase

68 of the 68 trials are tagged with Lennox Gastaut Syndrome itself; the rest are tagged with a narrower condition beneath it.

Get the Lennox Gastaut Syndrome report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Lennox Gastaut Syndrome trials start? (23)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 6

1992: 1 trials (Observational 1) 1993: 2 trials (Phase 3 2) 1997: 1 trials (Not applicable 1) 2003: 1 trials (Observational 1) 2005: 1 trials (Phase 3 1) 2007: 2 trials (Observational 1, Phase 3 1) 2008: 1 trials (Observational 1) 2010: 3 trials (Phase 4 1, Phase 3 2) 2011: 2 trials (Phase 4 1, Phase 3 1) 2012: 1 trials (Phase 3 1) 2013: 1 trials (Observational 1) 2015: 3 trials (Phase 3 3) 2016: 5 trials (Observational 1, Phase 3 2, Phase 2 1, Phase 1 1) 2017: 4 trials (Phase 3 2, Phase 1/2 1, Phase 1 1) 2018: 4 trials (Not applicable 1, Phase 2 2, Phase 1 1) 2019: 4 trials (Not applicable 1, Phase 3 1, Phase 1 2) 2020: 3 trials (Phase 4 1, Phase 3 1, Phase 1 1) 2021: 3 trials (Phase 4 1, Phase 3 2) 2022: 6 trials (Observational 1, Phase 3 2, Phase 2 2, Phase 1/2 1) 2023: 2 trials (Observational 1, Not applicable 1) 2024: 5 trials (Observational 1, Not applicable 1, Phase 3 2, Phase 2 1) 2025: 4 trials (Observational 1, Phase 3 2, Phase 1/2 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 4
2025 4
2024 5
2023 2
2022 6
2021 3
2020 3
2019 4
2018 4
2017 4

No forecast is made for this condition: it averages 4.2 trial starts a year over the five years to September, under the 5 a year the method needs.

Prediction, not a registry value: median of 35 months from start to primary completion across 8 trials still running at the 2026-10-09 snapshot; registered median of 33 months across 36 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Lennox Gastaut Syndrome trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 6
Phase 1/2 3
Phase 2 6
Phase 3 25
Phase 4 6
Not applicable 8
Observational 11
Expanded access 3

How many Lennox Gastaut Syndrome trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 4
Recruiting 5
Enrolling by invitation 3
Active, not recruiting 5
Available 2

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Lennox Gastaut Syndrome trials? (11)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Jazz Pharmaceuticals 7
Takeda 7
Longboard Pharmaceuticals 5
Eisai Inc. 4
SK Life Science, Inc. 4

Which drugs are being tested for Lennox Gastaut Syndrome? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cannabidiol 11
Soticlestat 5
Rufinamide 5
Carisbamate 4
LP352 4

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Topiramate IR 3
Epidiolex 100 mg/mL Oral Solution 2
Clobazam Low Dose 1
Clobazam Medium Dose 1
CanniMed® 1:20 1

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Lennox Gastaut Syndrome trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Status epilepticus 154 12
Pneumonia 139 15
Convulsion 112 4
Seizure 69 8
Pyrexia 40 7

Which publications cover Lennox Gastaut Syndrome? (32)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Prevalence (6)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Lennox-Gastaut syndrome Point prevalence 1-5 / 10 000 Europe Not stated Exact
Lennox-Gastaut syndrome Annual incidence 1-9 / 1 000 000 Europe Not stated Exact
Lennox-Gastaut syndrome Point prevalence 1-5 / 10 000 Europe Not stated Exact
Lennox-Gastaut syndrome Point prevalence 1-5 / 10 000 Europe Not stated Unspecified
Lennox-Gastaut syndrome Annual incidence 1-9 / 1 000 000 Europe Not stated Exact

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Lennox-Gastaut syndrome 2382 Exact Orphadata Science knowledge files, Product 1
Lennox-Gastaut syndrome 2382 Exact Orphanet Rare Disease Ontology (ORDO)

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages